Meyer Andrew Hollman
Chief Business Officer
Meyer Andrew Hollman has filed 4 SEC Form 4 filings (9 transaction rows) across 1 company, with disclosures dating back to 2025. 4 of those filings fall inside the rolling window. Most recent filing: Jan 2, 2026.
On the most recent filing, Meyer Andrew Hollman is listed as Chief Business Officer at Janux Therapeutics, Inc. Inside the rolling window, Meyer Andrew Hollman reported no open-market purchases and 4 open-market sales totaling $737K in JANX. The largest disclosed transaction in the window is a sale of 16,665 JANX shares on Oct 28, 2025, worth $501K.
Companies traded
Other insiders at JANX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$737K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Meyer Andrew Hollman made?
Meyer Andrew Hollman has filed 4 SEC Form 4 filings (9 transaction rows) across 1 company since 2025.
Which companies does Meyer Andrew Hollman trade?
Meyer Andrew Hollman has filed SEC Form 4 disclosures for 1 company, including JANX.
When was Meyer Andrew Hollman's most recent SEC Form 4 filing?
Meyer Andrew Hollman's most recent SEC Form 4 filing on Tracefour is dated Jan 2, 2026.
What is Meyer Andrew Hollman's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Meyer Andrew Hollman is listed as Chief Business Officer.
What is Meyer Andrew Hollman's total buy and sell value in the current window?
Inside the rolling retention window, Meyer Andrew Hollman bought $0 and sold $737K based on SEC Form 4 filings.
What was Meyer Andrew Hollman's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 16,665 JANX shares on 2025-10-28, worth $501K, per SEC Form 4 filings.